scispace - formally typeset
M

Muhammad Saddiq Zahari

Researcher at Johns Hopkins University

Publications -  13
Citations -  2186

Muhammad Saddiq Zahari is an academic researcher from Johns Hopkins University. The author has contributed to research in topics: Breast cancer & Receptor tyrosine kinase. The author has an hindex of 10, co-authored 13 publications receiving 1912 citations. Previous affiliations of Muhammad Saddiq Zahari include University of California, San Francisco & Johns Hopkins University School of Medicine.

Papers
More filters
Journal ArticleDOI

A draft map of the human proteome

Min-Sik Kim, +73 more
- 29 May 2014 - 
TL;DR: A draft map of the human proteome is presented using high-resolution Fourier-transform mass spectrometry to discover a number of novel protein-coding regions, which includes translated pseudogenes, non-c coding RNAs and upstream open reading frames.
Journal ArticleDOI

Activation of diverse signalling pathways by oncogenic PIK3CA mutations

TL;DR: It is demonstrated that phosphorylation of cortactin by AKT1 is important for mutant PI3K enhanced cell migration and invasion through mutagenesis studies, and a quantitative and global approach is described for identifying mutation-specific signaling events and for discovering novel signaling molecules as readouts of pathway activation or potential therapeutic targets.
Journal ArticleDOI

The non-receptor tyrosine kinase TNK2/ACK1 is a novel therapeutic target in triple negative breast cancer

TL;DR: It is demonstrated that knockdown of TNK2 expression can substantially suppress the invasiveness and proliferation advantage of TNBC cells in vitro and tumor formation in xenograft mouse models, and this study suggests thatTNK2 is a novel potential therapeutic target for the treatment of T NBC.
Journal ArticleDOI

Phosphoproteomic Analysis Identifies Focal Adhesion Kinase 2 (FAK2) as a Potential Therapeutic Target for Tamoxifen Resistance in Breast Cancer

TL;DR: Living analysis revealed that high expression of FAK2 is significantly associated with shorter metastasis-free survival in estrogen receptor-positive breast cancer patients treated with tamoxifen, and studies suggest that FAK 2 is a potential therapeutic target for the management of hormone-refractory breast cancers.